19 completed, 9 unknown, 3 active not recruiting, 2 not yet recruiting. 40 Phase 1, 10 Phase 2.
Follow Vaginitis: new trials by email Literature Review of Vaginitis trials Research Report on Vaginitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test New Investigational Drugs (LCFA-01and LC103) for Bacterial Vaginosis (BV) Treatment metronidazole (MTZ)+ LCFA-01 placebo + LC103 placebo, metronidazole (MTZ)+ LCFA-01 + LC103 placebo, metronidazole (MTZ)+ LC103 + LCFA-01 placebo - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Massachusetts General Hospital | 280 | 2027-02-03 | 2026-10-15 |
| A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV) GenSci142 capsule, clindamycin phosphate vaginal cream - Randomized, Open-label | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 42 | 2026-08-15 | 2026-10-15 |
| A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women GenSci142, Placebo GenSci142 - Bacterial Vaginosis | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 30 | 2025-12-01 | 2025-12-24 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and as Multiple Ascending Doses in Women Diagnosed With Bacterial Vaginosis BNT331, Placebo - Bacterial Vaginosis | Phase 1 | Completed | BioNTech SE | 102 | 2024-07-01 | 2026-10-05 |
| Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers CanProFem-AK - Candidosis Vaginal | Phase 1 | Completed | Industrial Microbiology LLP | 20 | 2024-06-01 | 2024-08-02 |
| Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study Vaccine - Recurrent Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Active not recruiting | LimmaTech Biologics AG | 251 | 2023-12-06 | 2026-03-04 |
| Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens Microbiological identification kits (ANAEROtest, STAPHYtest, ENTEROtest, NEFERMtest), Antibiotic therapy after the results of antibiotic sensitivity test (Mostly Oxacillin, Benzylpenicillin, Ceftriaxone, Doxycycline, Clindamycin), Suppositoria for vaginal microflora recovery (Giynoflor) - Bacterial Vaginosis | Phase 1 | Active not recruiting | Danylo Halytsky Lviv National Medical University | 200 | 2023-09-01 | 2024-09-27 |
| Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection | Phase 1 | Completed | Scynexis, Inc. | 5 | 2023-07-12 | 2025-08-08 |
| Safety, Tolerability, and Acceptability Study of Intravaginal Administration of LABTHERA-001 Capsules in Healthy Women Experimental: Low dose LABTHERA-001 capsule, Experimental: Medium dose LABTHERA-001 capsule, Experimental: High dose LABTHERA-001 capsule - Bacterial Vaginosis, Vaginal Disease | Phase 1 | Unknown | AtoGen Co. Ltd | 24 | 2022-11-02 | 2023-03-09 |
| First in Human Study in Healthy Volunteers of Antimicrobial Peptide PL-18 Vaginal Suppositories Dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories, Placebo dose 1 to 5 of Antimicrobial Peptide PL-18 Vaginal Suppositories - Colpomycosis, Bacterial Vaginosis | Phase 1 | Unknown | Protelight Pharmaceuticals Australia PTY LTD | 50 | 2022-08-01 | 2023-12-11 |
| Safety and Efficacy of Vaginal Microbiota Transplant (VMT) in Women With Bacterial Vaginosis (BV) Cervicovaginal secretions, Metronidazole gel, Screening tests - Bacterial Vaginosis | Phase 1 | Withdrawn | Johns Hopkins University | 2022-03-01 | 2021-11-03 | |
| Estrogen and Platelet Rich Plasma in Treatment of Atrophic Vaginitis Conjugated Estrogens vaginal cream 0,625mg, platelet rich plasma - Atrophic Vaginitis, Postmenopausal Atrophic Vaginitis | Phase 1 | Unknown | Fayoum University | 100 | 2021-11-13 | 2023-05-01 |
| Vaginal Microbiota Transplant Vaginal microbiome transplant, Oral Metronidazole, Sterile saline - Recurrent Bacterial Vaginosis | Phase 1 / Phase 2 | Recruiting | Douglas Kwon | 62 | 2021-04-22 | 2026-09-11 |
| Pharmacokinetic Study of DARE-BV1 DARE-BV1 - Bacterial Vaginosis | Phase 1 | Completed | Daré Bioscience, Inc. | 21 | 2020-11-03 | 2022-04-29 |
| Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis Vaginal Microbiome Transplantation (VMT), Placebo - Bacterial Vaginoses | Phase 1 / Phase 2 | Active not recruiting | Hadassah Medical Organization | 30 | 2020-08-20 | 2026-09-28 |
| Estrogen, Probiotics and Vaginal Health to Prevent HIV Infection in ACB Women Estring Vaginal Ring, RepHresh Pro-B - HIV-1-infection, Bacterial Vaginoses | Phase 1 | Completed | McMaster University | 50 | 2019-11-04 | 2021-12-17 |
| Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity Metronidazole Oral, Placebo Oral Tablet - Bacterial Vaginoses | Phase 1 | Terminated | The University of Texas Medical Branch, Galveston | 75 | 2019-10-11 | 2023-12-12 |
| Effect of PRP Injection in Releiving of Symptoms of Senile Vaginitis Platelet rich plasma - Senile Vaginitis | Phase 1 | Unknown | Ain Shams University | 30 | 2019-03-18 | 2019-04-02 |
| Patients With Vulvovaginal Candidiasis EPP-AF Gel 1%, EPP-AF Gel 2%, Clotrimazole - Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | University of Sao Paulo | 90 | 2018-01-30 | 2018-10-19 |
Showing 20 of 40. Sign in to see all of them.
Vaginosis, Bacterial (23) · Candidiasis, Vulvovaginal (10) · Atrophic Vaginitis (6) · Vaginal Diseases (3) · Bacterial Infections (2) · Candidiasis (2) · HIV Infections (2) · Mycoses (2) · Torulopsis (2) · Breast Neoplasms (1) · Candidiasis, Oral (1) · Dyspareunia (1) · Female Urogenital Diseases (1) · Genital Diseases, Female (1)
Female Urogenital Diseases and Pregnancy Complications (40) · Genital Diseases (40) · Urogenital Diseases (40) · Female Urogenital Diseases (39) · Genital Diseases, Female (39) · Vaginal Diseases (37) · Bacterial Infections and Mycoses (32) · Infections (32) · Bacterial Infections (22) · Vulvar Diseases (10) · Vulvitis (10) · Vulvovaginitis (10) · Candidiasis (8) · Mycoses (8)
Metronidazole (6) · Control Groups (2) · Estriol (2) · Amphotericin B (1) · Benchmarking (1) · Biological Products (1) · Ceftriaxone (1) · Clindamycin (1) · Clotrimazole (1) · Doxycycline (1) · Early Detection of Cancer (1) · Estradiol (1) · Estrogens, Conjugated (USP) (1) · Nystatin (1) · Penicillin G (1)
Changchun GeneScience Pharmaceutical Co., Ltd. (2) · The University of Texas Medical Branch, Galveston (2) · Ain Shams University (1) · AtoGen Co. Ltd (1) · BioNTech SE (1) · Biose (1) · CDA Research Group, Inc. (1) · Danylo Halytsky Lviv National Medical University (1) · Daré Bioscience, Inc. (1) · Douglas Kwon (1) · Faith Mediplex (1) · Fayoum University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Hadassah Medical Organization (1) · Industrial Microbiology LLP (1)
United States (13) · China (4) · Australia (3) · Belgium (3) · Canada (2) · Egypt (2) · Israel (2) · Brazil (1) · France (1) · Germany (1) · Japan (1) · Kazakhstan (1) · Kenya (1) · Nigeria (1) · Poland (1)
Ahinoam Lev-Sagie (1) · Alan Bocking, MD, FRCSC (1) · Ashwin Chatwani, MD (1) · Christine Mauck, MD (1) · Christopher Argent, Dr. (1) · Christopher Moller, Dr. (1) · Craig Cohen, MD, MPH (1) · Doug Kwon, MD, PhD (1) · Gabe Nussbaum, MD, PhD (1) · Gilbert Donders, Prof. Dr. (1) · Giuseppe Pantaleo, Prof (1) · Hans Verstraelen, Prof. dr. (1)
PMID 24718774, PMID 25427450, PMID 26223323, PMID 27093291, PMID 29697768, PMID 39836666, PMID 41291715
2014 (1), 2023 (1)